drugset / Trial / NCT00075894

Alanosine in Treating Patients With Progressive or Recurrent Malignant Gliomas

NCT00075894 ↗

Phase 1 Completed 18 enrolled National Cancer Institute (NCI)
Open-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as alanosine, use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of alanosine in treating patients with high-grade progressive or recurrent malignant gliomas.

Timeline

Start
2004-03
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject alanosine Small molecule — Intravenous
Subject alanosine Small molecule — —